58553-48-3

Usage

Uses

Used in Chemical Synthesis:
2-Cyano-5-hydroxymethylpyridine is used as a chemical intermediate for the synthesis of various complex organic compounds. Its unique structure allows for the formation of new bonds and reactions, making it a valuable component in the creation of novel molecules.
Used in Pharmaceutical Industry:
2-Cyano-5-hydroxymethylpyridine is used as a building block in the development of new pharmaceutical compounds. Its functional groups, such as the cyanide and hydroxymethyl groups, can be utilized to create new drug molecules with potential therapeutic applications.
Used in Research and Development:
2-Cyano-5-hydroxymethylpyridine is used as a research compound in academic and industrial laboratories. Its properties and reactivity can be studied to gain insights into the behavior of similar compounds and to develop new synthetic methods and applications.

InChI:InChI=1/C7H6N2O/c8-3-7-2-1-6(5-10)4-9-7/h1-2,4,10H,5H2

Upstream product

• 89809-65-4 methyl 6-cyanopyridine-3-carboxylate 
• 149806-06-4 6-bromonicotinaldehyde 
• 131747-68-7 2-cyanopyridine-5-carboxyaldehyde 
• 557-21-1 zinc(II) cyanide 
• 122306-01-8 2-bromo-5-(hydroxymethyl)pyridine 
• 26218-78-0 methyl 6-bromonicotinate 
• 887579-62-6 5-cyano-3-pyridinecarboxylic acid 
• 1620-77-5 5-methylpicolinonitrile 
• 70165-31-0 6-cyanonicotinic acid 
• 114951-34-7 3-Acetoxymethylpyridine-N-oxide 
• 131747-37-0 3-Acetoxymethyl-6-cyanopyridine 

Downstream Products

• 131747-68-7 2-cyanopyridine-5-carboxyaldehyde 
• 108337-86-6 2,6-dimethyl-4-(6-cyano-3-pyridyl)-1,4-dihydropyridine-3,5-dicarboxylic acid 3-β-(N-benzyl-N-methylamino)ethyl ester 5-methyl ester 
• 105954-37-8 5-chloromethyl-pyridine-2-carbonitrile 
• 302341-61-3 tert-bulyl N-[(6-cyanopyridin-3-yl)methyl]carbamate 
• 609345-79-1 5-(aminomethyl)pyridine-2-carboximidamide 
• 181130-14-3 5-(aminomethyl)pyridine-2-carbonitrile 
• 421551-72-6 (6-cyanopyridin-3-yl)methyl methanesulfonate 
• 1225380-31-3 5-(chloromethyl)pyridine-2-carbonitrile hydrochloride 

Relevant academic research and scientific papers

Heterocyclic phosphodiesterase inhibitor and uses thereof

The present invention belongs to the technical field of medicine, and particularly relates to a heterocyclic phosphodiesterase inhibitor compound represented by a formula (I), or a pharmaceutically acceptable salt and a stereoisomer thereof, and a pharmaceutical preparation, a pharmaceutical composition and applications of the compound, wherein R1, R2, R3, R4, ring A, m and n are defined in the specification. According to the present invention, the compound can be used for preparing drugs for treatment or prevention of diseases associated with PDE9 kinase.

Improving the Selectivity of PACE4 Inhibitors through Modifications of the P1 Residue

Paired basic amino acid cleaving enzyme 4 (PACE4), a serine endoprotease of the proprotein convertases family, has been recognized as a promising target for prostate cancer. We previously reported a selective and potent peptide-based inhibitor for PACE4, named the multi-Leu peptide (Ac-LLLLRVKR-NH2 sequence), which was then modified into a more potent and stable compound named C23 with the following structure: Ac-dLeu-LLLRVK-Amba (Amba: 4-amidinobenzylamide). Despite improvements in both in vitro and in vivo profiles of C23, its selectivity for PACE4 over furin was significantly reduced. We examined other Arg-mimetics instead of Amba to regain the lost selectivity. Our results indicated that the replacement of Amba with 5-(aminomethyl)picolinimidamide increased affinity for PACE4 and restored selectivity. Our results also provide a better insight on how structural differences between S1 pockets of PACE4 and furin could be employed in the rational design of selective inhibitors.

Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use

In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R1, R2, R3, R4, R5, R9, ring A, ring B, m, n, p, -L1-, -L2-, and -L3- is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

THERAPEUTIC AGENT FOR CEREBRAL INFARCTION

The present invention provides a novel therapeutic drug for cerebral infarction, which contains a piperazine compound as an active ingredient. The compound of the present invention can be provided as a novel therapeutic drug for cerebral infarction having

HETEROCYCLIC DERIVATIVES

The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

DIHYDROPYRIDINONE DERIVATIVES

The invention relates to novel dihydropyridinone derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

PYRIMIDINONE DERIVATIVES AS THERAPEUTIC AGENTS AGAINST ACUTE AND CHRONIC INFLAMMATORY, ISCHAEMIC AND REMODELLING PROCESSES

The invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases.

Mandelic acid derivatives and their use as throbin inhibitors

There is provided a compound of formula I wherein Ra, R1, R2, Y and R3 have meanings given in the description and pharmaceutically acceptable derivatives (including prodrugs) thereof, which compounds and derivatives are useful as, or are useful as prodrugs of, competitive inhibitors of trypsin-like proteases, such as thrombin, and thus, in particular, in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

PHARMACEUTICAL COMBINATION

There is provided a combination product comprising: (1) a compound of claim 1 in WO 02/44145 or a compound of claim 20 in WO 02/44145 (or derivative thereof)or a pharmaceutically-acceptable derivative thereof; and (1) a compound as defined in claim 1 of WO 01/28992 or (2) a compound of Claim 34 of WO 01/28992 or (3) Compound A or B or C or D (or pharmaceutically-acceptable salts thereof) for use in treating arrhythmia or a coagulation controlled complication thereof.

Substituted phenyl farnesyltransferase inhibitors

Compounds of formula (I) or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.